ERCC1、BRCA1、RRM1表达在晚期非小细胞肺癌个体化治疗中的前瞻性研究

Abstract
Figure/Table
References (16)
Related Citation (1)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the application value of excision repair cross-complementing gene 1(ERCC1),breast cancer susceptibility gene 1 (BRCA1),and ribonucleotide reductase M1 subunit(RRM1)expression in the individualized treatment of advanced non-small cell lung cancer(NSCLC).MethodsFrom June 2015 to August 2016,50 patients with advanced NSCLC visited our hospital were recruited as research subjects.Using an odd/even number grouping model,they were grouped and there were 25 cases in each group.In the experimental group,the level of ERCC1,BRCA1,and RRM1 were tested,and the corresponding chemotherapy regimen was selected based on the outcomes.In the conventional group,Gemcitabine combined with Cisplatin was provided.The therapeutic effect was compared between the two groups.ResultsThe total effective rate of chemotherapy in the experimental group was 72.00%,which was obviously higher than that of the conventional group,and there was a statistical difference(P＜0.05).The quality of life in both groups was improved compared with that before chemotherapy,but there was no significant difference of PS score between the two groups(P＞0.05).In the experimental group,there were blood system reaction in 12 cases,digestive tract reaction in 7 cases,and other in 3 ones.In the conventional group,there were blood system reaction in 13 cases,digestive tract reaction in 7 cases,and other in 3 ones.There was no statistical difference of the incidence of adverse reaction between the two groups(P＞0.05).ConclusionTest for the level of ERCC1,BRCA1,and RRM1 and guidance of clinical treatment in NSCLC patients based on the outcomes are beneficial to improve the clinical therapeutic effect.

Key words： Advanced non-small cell lung cancer Individualized treatment ERCC1 BRCA1 RRM1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DING Jian-wu
	TANG Luo-yong
	AI Su-fen
	ZHANG Feng-hao
	HUANG Long
	HU Rong-huan
	XIONG Qiang

Cite this article:

DING Jian-wu,TANG Luo-yong,AI Su-fen, et al. Prospective study of ERCC1,BRCA1,and RRM1 expression on the individualized treatment of advanced non-small cell lung cancer[J]. 中国当代医药, 2017, 24(32): 56-58.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I32/56

[1]	李铁志，石彦涛，高少林，等.ERCC1、RRM1 与 BRCA1 蛋白联合检测在非小细胞肺癌治疗中的价值分析[J].中国医学前沿杂志（电子版），2015，7（12）：36-39.
[2]	白娟，郑玲，李茨，等.联合检测 ERCC1、BRCA1、RRM1 表达在非小细胞肺癌选择化疗方案中的意义[J].现代肿瘤医学，2016，24（21）：3410-3413.
[3]	文亢，李俊，李东斌，等.BRCA1 RRM1及ERCC1基因多态性与非小细胞肺癌化疗疗效相关性分析[J].浙江临床医学，2016，18（3）：428-430.
[4]	Laura Bonanno，杨雯.晚期非小细胞肺癌个体化化疗的预测因子[J].临床与病理杂志，2015，35（4）：E94-E103.
[5]	郭珺，王哲海，刘琳，等.非小细胞肺癌组织 ERCC1和RRM1基因表达及其对预后影响探讨[J].中华肿瘤防治杂志，2014，21（20）：1594-1597.
[7]	罗静，徐美青，郭明发，等.非小细胞肺癌组织中ERCC1、RRM1和β-tubulinⅢ的表达及意义[J].中国老年学杂志，2016，36（5）：1113-1116.
[8]	郭燕，谭清和，吉志固，等.403例非小细胞肺癌组织/细胞中ERCC1、RRM1及β-tubulinⅢ的免疫组化和原位杂交检测[J].江苏医药，2014，40（1）：27-30，封 2.
[6]	尹志永，杨大勇，杨立丰，等.切除修复交叉互补基因1、核糖核苷酸还原酶M1亚基和3型β微管蛋白分子检测指导晚期非小细胞肺癌个体化治疗的临床效果[J].中国医药导报，2016，13（2）：81-84.
[9]	邢舴，呼群，苏乌云，等.非小细胞肺癌免疫组化指标的表达与EGFR基因突变的相关性[J].医学研究生学报，2017，30（3）：275-278.
[10]	田玉旺，许春伟，高文斌，等.非小细胞肺癌组织中表皮生长因子受体基因突变与ERCC1和RRM1 mRNA表达的关系[J].中华肺部疾病杂志（电子版），2014，7（1）：27-31.
[11]	申潞艳，康晓征，孙宇，等.非小细胞肺癌切除组织中常用免疫组织化学指标尚不能预测远期生存[J].中国肺癌杂志，2016，19（3）：147-152.
[12]	朱铁峰，崔贵，景凯，等.ERCC1、RRM1、TYMS、TUBB3 表达对晚期非小细胞肺癌个体化治疗的应用分析[J].中国临床研究，2015，28（6）：736-739.
[13]	周成伟.非小细胞肺癌中ERCC1和RRM1的表达及临床意义[J].中华全科医学，2016，14（6）：981-983.
[14]	李远航，代祖建，何锋，等.非小细胞肺癌肺叶切除术后的个体化治疗[J].齐齐哈尔医学院学报，2014，35（4）：523-524.
[15]	孙江涛，原翔，宋开放，等.肺癌组织中切除修复交叉互补基因1和核糖核苷酸还原酶亚单位1表达水平与非小细胞肺癌患者的疗效和生存期的关系[J].新乡医学院学报，2017，34（4）：270-274.
[16]	尹志永，杨大勇，杨立丰，等.多种分子检测对晚期非小细胞肺癌辅助治疗的临床研究[J].临床肺科杂志，2016，21（5）：947-950.